RENB vs. CVAC, CNTA, SPRY, TYRA, ZNTL, IRON, PRAX, EOLS, ETNB, and NRIX
Should you be buying Renovaro stock or one of its competitors? The main competitors of Renovaro include CureVac (CVAC), Centessa Pharmaceuticals (CNTA), ARS Pharmaceuticals (SPRY), Tyra Biosciences (TYRA), Zentalis Pharmaceuticals (ZNTL), Disc Medicine (IRON), Praxis Precision Medicines (PRAX), Evolus (EOLS), 89bio (ETNB), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical preparations" industry.
CureVac (NASDAQ:CVAC) and Renovaro (NASDAQ:RENB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, community ranking, media sentiment, risk, profitability, analyst recommendations and dividends.
CureVac has a beta of 2.51, indicating that its stock price is 151% more volatile than the S&P 500. Comparatively, Renovaro has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500.
CureVac received 22 more outperform votes than Renovaro when rated by MarketBeat users.
Renovaro has lower revenue, but higher earnings than CureVac. CureVac is trading at a lower price-to-earnings ratio than Renovaro, indicating that it is currently the more affordable of the two stocks.
17.3% of CureVac shares are held by institutional investors. Comparatively, 71.4% of Renovaro shares are held by institutional investors. 2.2% of CureVac shares are held by insiders. Comparatively, 21.7% of Renovaro shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Renovaro has a net margin of 0.00% compared to Renovaro's net margin of -463.49%. Renovaro's return on equity of -49.22% beat CureVac's return on equity.
CureVac presently has a consensus target price of $8.33, indicating a potential upside of 114.22%. Given Renovaro's higher possible upside, analysts clearly believe CureVac is more favorable than Renovaro.
In the previous week, CureVac had 4 more articles in the media than Renovaro. MarketBeat recorded 6 mentions for CureVac and 2 mentions for Renovaro. CureVac's average media sentiment score of 1.09 beat Renovaro's score of 0.52 indicating that Renovaro is being referred to more favorably in the news media.
Summary
CureVac beats Renovaro on 8 of the 15 factors compared between the two stocks.
Get Renovaro News Delivered to You Automatically
Sign up to receive the latest news and ratings for RENB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RENB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Renovaro Competitors List
Related Companies and Tools
